Shustik, J. “Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor”. Canadian Hematology Today, vol. 4, no. 3, Dec. 2025, pp. 24–35, doi:10.58931/cht.2025.4379.